Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962749 | PMC |
| http://dx.doi.org/10.1016/j.hrcr.2019.10.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MCPIP1 Controls Hybrid EMT and Tumor Stemness via the IL6/JAK2/STAT3 Axis in Pancreatic Cancer.
Cancer Med
September 2025
Department of Anatomy, Anhui Medical University, Hefei, Anhui, China.
Introduction: Pancreatic cancer (PC) is a common malignant tumor with high morbidity and mortality and a very poor prognosis, highlighting the urgent need to identify molecular therapeutic targets. Monocyte chemotactic protein-inducible protein-1 (MCPIP1) is a common inflammatory protein associated with the pathogenesis of a variety of cancers, although a comprehensive understanding of its function and the underlying mechanisms involved in PC remains unclear.
Materials And Methods: Immunohistochemistry, western blotting, immunofluorescence, flow cytometry, Transwell, and the scratch assay were used to evaluate the functional role of MCPIP1 in PC.
Effect of miR-6767-5p on breast cancer cell phenotype and its regulatory mechanism.
Sci Rep
August 2025
Department of Clinical Medicine, Guizhou Medical University, No. 9 of Beijing Road, Guiyang, 550004, Guizhou, P. R. China.
Unlabelled: Objective To investigate the role and mechanism of miR-6767-5p in breast cancer (BC).
Methods: We explored the effects of miR-6767-5p on the proliferation, migration, and invasion of BC cells in vitro and in vivo through CCK-8, EdU, Transwell, and subcutaneous tumorigenesis experiments in nude mice and a tail vein lung metastasis model. Cysteine-rich intestinal protein 2 (CRIP2) was validated as a target gene of miR-6767-5p through dual-luciferase reporter assays, quantitative polymerase chain reaction (qPCR), and western blot (WB) analysis.
Clinical and Economic Impact of Hybrid Closed-Loop Systems for T1 Diabetes Management in Spain.
Endocr Pract
August 2025
Department of Endocrinology and Nutrition, Hospital Universitario de Badajoz, Badajoz, Spain; Universidad de Extremadura, Badajoz, Spain.
Objective: The main challenge in type 1 diabetes mellitus management is achieving and maintaining glycemic control. Hybrid closed-loop (HCL) systems offer patients the potential to safely achieve tight glycemic targets. This study analyzed the clinical and economic impact of HCL systems compared with intermittently scanned continuous glucose monitoring (is-CGM) and continuous subcutaneous insulin infusion (CSII) therapy from the Spanish health care system perspective.
View Article and Find Full Text PDFEvaluation of Glycemia Risk Index and Continuous Glucose Monitoring Outcomes Following the Transition to an Advanced Hybrid Closed-Loop System in Type 1 Diabetes.
Adv Ther
August 2025
Department of Endocrinology and Diabetes, Diabetes Treatment Center, Prince Sultan Military Medical City, P.O. Box 7897, 11159, Riyadh, Saudi Arabia.
Introduction: Advanced hybrid closed-loop (AHCL) systems have shown promise in improving glycemic control in adults with type 1 diabetes (T1D), yet real-world evidence remains limited. This study evaluated the impact of transitioning from multiple daily injections (MDI) or conventional continuous subcutaneous insulin infusion (CSII) to the Tandem t:slim X2™ Control-IQ® AHCL system on glycemic outcomes in adults with T1D.
Methods: In this retrospective study, 56 non-pregnant adults with T1D were followed for 6 months.
Amphotericin B intercalated in layered clays as effective antifungal systems against eumycetoma causative agents.
Int J Pharm
October 2025
Instituto de Ciencia de Materiales de Madrid (ICMM), CSIC, Madrid 28049, Spain.
Eumycetoma and other subcutaneous mycosis are severe chronic infections with a high incidence in tropical and subtropical regions, whose current treatment has a low curation rate. In the search for more effective and affordable therapies, hybrid materials based on amphotericin B (AmB), an antifungal drug with a broad spectrum of action, appear promising for localized treatment at the site of infection. In this context, the immobilization of AmB in suitable nanocarriers would be helpful to minimize its adverse side effects and ensure a controlled release over time.
View Article and Find Full Text PDF